Medicine for preventing restenosis after intracoronary stent implantation and preparation method thereof

A technology of restenosis and drugs, which is applied in the field of medicine, can solve problems such as bleeding, affecting long-term curative effect, and patients with peptic ulcer, and achieve the effects of improving quality of life, improving chest tightness and pain, and good social and economic benefits

Inactive Publication Date: 2013-04-24
张新元
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The incidence of postoperative restenosis (RS) and in-stent restenosis (ISR) is still as high as 10% to 50%, which seriously affects the long-term efficacy
[0003] At present, there are many drugs for the prevention of ISR

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine for preventing restenosis after intracoronary stent implantation and preparation method thereof
  • Medicine for preventing restenosis after intracoronary stent implantation and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0048]

[0049]

[0050] From January 2007 to January 2012, a total of 605 patients with coronary heart disease were treated in our hospital. From the perspective of safety and sample size, 363 patients with successful coronary stenting were selected for research.

[0051] All patients were in line with the treatment indications of the "Guidelines for Percutaneous Coronary Intervention" formulated by the Cardiovascular Branch of the Chinese Medical Association in 2002. Intracoronary stenting was performed and met success criteria. And within 6 months after coronary stent implantation, coronary angiography confirmed significant coronary artery stenosis (>50%).

[0052] Methods: 350 eligible persons were randomly selected and randomly divided into a treatment group of 280 cases and a control group of 70 cases. The control group routinely took 100 mg of aspirin tablets (produced by Bayer, Germany), once a day, and 75 mg of clopidogrel tablets (produced by Plavix) (produced b...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a medicine for preventing restenosis after the intracoronary stent implantation, which is characterized by comprising the components in parts by mass as follows: 200-250 parts of astragalus mongholicus, 35-50 parts of ginseng, 65-85 parts of radix ophiopogonis, 220-245 parts of salvia miltiorrhiza, 65-90 parts of lignum dalbergiae odoriferae, 100-130 parts of fructus aurantii, 100-125 parts of ligusticum wallichii, 105-130 parts of poria cocos, 65-90 parts of processed rhizoma pinelliae, 105-135 parts of trichosanthes kirilowii maxim, 85-105 parts of allium macrostemon, 105-138 parts of pericarpium citri reticulatae and 60-85 parts of liquorice. Compared with the prior art, the medicine can prevent a restenosis phenomenon after the intracoronary stent implantation, effectively relieve angina, and prevent and treat in-stent restenosis.

Description

technical field [0001] The invention belongs to the field of medicine, in particular to a medicine for preventing restenosis after coronary stent implantation and a preparation method thereof. Background technique [0002] With the general improvement of people's living standards, the incidence of coronary atherosclerotic heart disease (CHD) has increased year by year, and has become the first killer of human health in recent years. Percutaneous transluminal coronary angioplasty (PTCA) is one of the best methods for coronary revascularization and a breakthrough in the treatment of coronary heart disease. Its appearance is a milestone in the treatment of coronary heart disease. Etc. Postoperative restenosis (RS) and in-stent restenosis (ISR) incidence rates are still as high as 10% to 50%, seriously affecting the long-term efficacy. [0003] At present, there are many drugs for the prevention of ISR, and the dual-antibody method, that is, aspirin plus clopidogrel, is usuall...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K36/8968A61P9/10
Inventor 张新元张淑霞王强
Owner 张新元
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap